The ovarian cancer drugs market is expanding due to rising incidence rates, increasing use of PARP inhibitors, and advancements in targeted and immunotherapies enhancing patient survival outcomes. https://www.datamintelligence.com/research-report/ovarian-cancer-drugs-market